Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIT565 in Systemic Lupus Erythematosus (SLE)
NCT06335979Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Nov 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of PIT565 in systemic lupus erythematosus (SLE) (8 cohorts), sponsored by Novartis. Primary endpoint: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs). Started Oct 2024; status: active, not recruiting.
02
Drugs
PIT565
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06335979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335979.